PRESS-RELEASE ·Filed Apr 15, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release: earnings
Actionable Insight • Neutral

Traders should prepare for Q1 2026 earnings release on May 6, 2026. The prior quarter's strong beat may raise expectations, but no guidance for current quarter is provided. Monitor for updates on product performance and revenue trends during the call.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ARQT ▲ +12.11% at T+60d
NEUTRAL call ✓ call won +12.11% · α vs SPY +5.07% · entry $24.19 → $27.12
Entry anchored
Apr 15, 03:59 PM ET
via exchange tick
T+1d
+1.41%
call +1.41% · α +0.19%
$24.53
settled 6mo ago
T+5d
-5.50%
call -5.50% · α -6.48%
$22.86
settled 5mo ago
T+20d
-10.33%
call -10.33% · α -16.15%
$21.69
settled 5mo ago
T+60d
+12.11%
call +12.11% · α +5.07%
$27.12
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Arcutis Biotherapeutics (ARQT) announced it will report Q1 2026 financial results on May 6, 2026, after market close. The press release contains no actual financial results for Q1 2026 but references a prior earnings beat in Q4 2025 where EPS was $0.13 vs. consensus of $-0.04, a 454.5% beat.

Key Financial Metrics

EPS
$0.13
est $-0.04 · +454.5%
Revenue
$105.3M
est $105.3M · 0.0%
Rating
in line

Key Facts

  • Company to report Q1 2026 financial results on May 6, 2026
  • No actual Q1 2026 financials disclosed in this release
  • Reference to Q4 2025 EPS of $0.13 (consensus: $-0.04), a 454.5% beat
  • Conference call scheduled for May 6, 2026 at 4:30pm ET

Financial Impact

No immediate financial impact from this announcement — forward-looking only

revenueeps

Risk Factors

  • Forward-looking statements subject to risks in business, reimbursement, and competition
  • No confirmation of revenue or earnings trends for Q1 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3274854
17 reports for ARQT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +14.74%Mar 2, 2026
Filters
Rows
Reports for ARQT — sortable, filterable
TypeNow
Aug 24, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.86 $26.38▲ +6.11%▲ +5.87%$25.16 (+1.21%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.08 $25.96▲ +3.51%▲ +4.04%$25.16 (+0.32%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.35 $25.38▲ +0.12%▲ +0.12%$25.16 (−0.75%)
Aug 11, 2026
7w ago
144
NEUTRAL ★ 3/10
$26.28 $23.38▼ −11.04%▼ −9.14%$25.16 (−4.26%)
Aug 6, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 5, 2026
8w ago
Press Release
BULLISH ★ 7/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 3, 2026
8w ago
144
NEUTRAL ★ 2/10
$26.03 $23.75▼ −8.76%▼ −7.52%$25.16 (−3.34%)
Jun 29, 2026
13w ago
Press Release
BULLISH ★ 7/10
$26.22 $27.84▲ +6.18%▲ +7.21%$25.16 (−4.04%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.21 $27.74▲ +5.84%▲ +5.30%$25.16 (−4.01%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$23.23 $28.78▲ +23.89%▲ +20.27%$25.16 (+8.31%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (64h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 15, 2026